Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with B cell non-Hodgkin lymphoma, as classified by the World Health Organization (WHO) 2017 guidelines
• People whose cancer has come back or gotten worse, and for whom standard treatments are no longer an option due to reasons such as intolerance, the treatments not working well enough, or no standard treatments being currently available
• People with a general health and activity level rated as 0 or 1 on the ECOG scale, meaning they are either fully active or have only minor limitations in physically demanding activity (confirm with trial site)
• People whose blood, kidney, liver, lung, heart, and bone marrow are functioning adequately, without having needed a blood transfusion in the two weeks before screening
• People with a life expectancy of at least 12 weeks
• Women who are able to become pregnant and have a negative pregnancy test (blood or urine) during the trial
• People who have given written consent to participate voluntarily in the trial

Who may not be able to join:

• People who have previously been treated with an allogeneic stem cell transplant (a transplant using cells from a donor)
• People who have a known allergy or sensitivity to the trial treatment (AT101) or to tocilizumab, or to chemotherapy drugs used for lymphodepletion (a preparatory treatment given before cell therapy) (confirm with trial site)
• People who are unable to donate their own blood for use in the trial
• People who have received chemotherapy or radiation therapy — other than lymphodepletion — within two weeks before receiving the trial treatment
• People who have not yet recovered from side effects of previous treatments, where recovery is defined as returning to a mild level or back to their baseline health (CTCAE grade 1 or lower) (confirm with trial site)
• People who have a condition that the trial investigators believe could affect their safety or the reliability of the trial results
• People who, at the time of screening, have any of the following:
  • A clinically significant heart condition diagnosed within the past 6 months
  • A blood clot, pulmonary embolism (a clot in the lungs), or a bleeding disorder identified within the past 6 months
  • A history of a cancer other than B cell non-Hodgkin lymphoma within the past 5 years
  • Major surgery within the past 4 weeks
  • Minor (non-critical) surgery within the past 2 weeks
• Women who are able to become pregnant, or men, who are not willing to use effective contraception during the trial and for at least 12 months after the last dose of AT101, or until AT101 is no longer detectable in the body
• People who have participated in another clinical trial or received another investigational treatment within 4 weeks of screening
• People with alcohol or drug dependency
• People who the principal investigator considers unfit or unable to participate in the trial for any reason

Important: Always verify eligibility with the trial site directly before applying.